CONFIRMATION-HF: CPC Clinical Research / #COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure

CONFIRMATION HF Abstract This study will find out whether finerenone and empagliflozin (the drugs used in this study) can lower the risk of heart failure and death and improve symptoms in patients hospitalized with heart failure. The study explores using these in combination, with early initiation compared to usual care which would not typically start this combination in the hospital setting. Approximately 1500 people are expected to take part in the study. This is a pragmatic, randomized, controlled, open-label, parallel arm, multicenter study evaluating the hypothesis that among adults hospitalized with acute heart failure (HF), an early, intensive management strategy with the combination of finerenone plus sodium-glucose co- transporter 2 inhibitor (SGLT2i) improves clinical outcomes compared with standard of care, and is well tolerated.